Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

• Status: Withdrawn
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Ipilimumab

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed malignant melanoma

• Stage III (unresectable) or Stage IV disease which may have been treated with up to one prior cytotoxic chemotherapy and/or up to 3 other therapeutic regimens

• Willing to undergo up to 3 biopsies of an accessible lesion

Exclusion Criteria:

• Active/symptomatic brain metastases

• Primary ocular melanoma or primary tumor of unknown origin

• Concurrent autoimmune disease

• Previous treatment with a CD137 agonist or CTLA-4 inhibitor